EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP) will announce its first-quarter financial results for the period ending March 31, 2020, after market close on May 13, 2020. A conference call and webcast will be held on May 14, 2020, at 8:30 am EDT, featuring CEO Marc Oczachowski and CFO François Dietsch.

EDAP TMS specializes in minimally invasive medical devices for urology, leveraging ultrasound technology. Their products include the Focal One® and Ablatherm® systems for prostate tissue ablation, as well as the Sonolith® systems for shock wave lithotripsy.

Positive

• Company set to release Q1 results, indicating ongoing business activity.
• Continued leadership in therapeutic ultrasound market, supporting long-term growth.

Negative

• None.

Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT

LYON, France, May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the markets close on Wednesday, May 13, 2020.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, May 14, 2020. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, May 14^th @ 8:30am Eastern Time
Domestic:                    877-451-6152
International:              201-389-0879
Passcode:                    13703225
Webcast:                     http://public.viavid.com/index.php?id=139678

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

CONTACTS:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com

 

 

FAQ

When will EDAP report its financial results?

EDAP will report its financial results for Q1 on May 13, 2020.

What time is the conference call for EDAP's Q1 results?

The conference call is scheduled for May 14, 2020, at 8:30 am EDT.

Who will present on the EDAP conference call?

CEO Marc Oczachowski and CFO François Dietsch will present during the call.

What products does EDAP TMS SA focus on?

EDAP focuses on minimally invasive medical devices for urology, including the Focal One® and Ablatherm® systems.